Compare MNTK & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNTK | KRRO |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.8M | 150.0M |
| IPO Year | 2020 | 2019 |
| Metric | MNTK | KRRO |
|---|---|---|
| Price | $1.20 | $12.68 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $4.00 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 366.6K | 257.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $176,382,000.00 | $6,392,000.00 |
| Revenue This Year | $18.55 | N/A |
| Revenue Next Year | $12.68 | N/A |
| P/E Ratio | $118.00 | ★ N/A |
| Revenue Growth | 0.37 | ★ 181.46 |
| 52 Week Low | $1.07 | $5.20 |
| 52 Week High | $2.78 | $55.89 |
| Indicator | MNTK | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 42.75 | 54.25 |
| Support Level | $1.07 | $12.17 |
| Resistance Level | $1.27 | $14.96 |
| Average True Range (ATR) | 0.08 | 1.00 |
| MACD | 0.02 | 0.18 |
| Stochastic Oscillator | 62.50 | 48.90 |
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.